Insider · CIK 0001643071
Atul Pande
Files at IMVT (Immunovant, Inc.). First filing Dec 5, 2023, latest Aug 28, 2026.
In brief
Atul Pande files SEC Form 4 as director at IMVT (Immunovant, Inc.). Since Dec 5, 2023, Atul Pande has reported 0 open-market buys worth $0 and 7 open-market sells worth $1.1M, the latest filed on Aug 28, 2026.
A track record needs three past buys with six months of prices behind them; Atul Pande has 0, so none is measured yet.
The newest scored trade: sold $65k of IMVT on Aug 28, 2026, filed Aug 28, 2026, scored 0 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 5 sells worth $425k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
IMVT: Immunovant, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 0Weak | Immunovant, Inc. | $65k 1,500 shares | -1% | +180% from low-8% from high | |
| 2Weak | Immunovant, Inc. | $60k 1,500 shares | -1% | +168% from low-4% from high | |
| 2Weak | Immunovant, Inc. | $57k 1,500 shares | -1% | +164% from low0% from high | |
| 2Weak | Immunovant, Inc. | $51k 1,500 shares | -1% | +128% from low-6% from high | |
| 7Weak | Immunovant, Inc. | $192k 6,000 shares | -5% | +152% from low0% from high | |
| 22Weak | Immunovant, Inc. | $221k 7,750 shares | -8% | - | |
| 33Weak | Immunovant, Inc. | $491k 12,350 shares | -13% | +192% from low0% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jun 15, 2026 | IMVT IMMUNOVANT, INC. | 6,000 0.00% of outstanding | $202k | Jun 15, 2026 | $192k |
| May 20, 2026 | IMVT IMMUNOVANT, INC. | 6,000 0.00% of outstanding | $158k | May 20, 2026 | none |
| Dec 2, 2024 | IMVT IMMUNOVANT, INC. | 7,750 0.01% of outstanding | $219k | Dec 2, 2024 | none |
| Dec 1, 2023 | IMVT IMMUNOVANT INC | 12,350 0.01% of outstanding | $483k | Dec 1, 2023 | none |
Transactions
Every row this insider has filed, 23 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 28, 2026 | IMVT Immunovant, Inc. | MOption exercise Common Stock10b5-1 | +1,500 | $8.43 | $13k | 118,231 | Aug 28, 2026 |
| Aug 28, 2026 | IMVT Immunovant, Inc. | SOpen-market sale Common Stock10b5-1 | -1,500 | $43.27 | $65k | 116,731 | Aug 28, 2026 |
| Aug 28, 2026 | IMVT Immunovant, Inc. | MOption exercise Stock Option (right to buy)derivative10b5-1 | -1,500 | $0.00 | $0 | 65,181 | Aug 28, 2026 |
| Jul 24, 2026 | IMVT Immunovant, Inc. | MOption exercise Common Stock10b5-1 | +1,500 | $8.43 | $13k | 118,231 | Jul 24, 2026 |
| Jul 24, 2026 | IMVT Immunovant, Inc. | SOpen-market sale Common Stock10b5-1 | -1,500 | $39.80 | $60k | 116,731 | Jul 24, 2026 |
| Jul 24, 2026 | IMVT Immunovant, Inc. | MOption exercise Stock Option (right to buy)derivative10b5-1 | -1,500 | $0.00 | $0 | 66,681 | Jul 24, 2026 |
| Jun 26, 2026 | IMVT Immunovant, Inc. | MOption exercise Common Stock10b5-1 | +1,500 | $8.43 | $13k | 118,231 | Jun 26, 2026 |
| Jun 26, 2026 | IMVT Immunovant, Inc. | SOpen-market sale Common Stock10b5-1 | -1,500 | $38.01 | $57k | 116,731 | Jun 26, 2026 |
| Jun 26, 2026 | IMVT Immunovant, Inc. | MOption exercise Stock Option (right to buy)derivative10b5-1 | -1,500 | $0.00 | $0 | 68,181 | Jun 26, 2026 |
| Jun 15, 2026 | IMVT Immunovant, Inc. | MOption exercise Common Stock10b5-1 | +1,500 | $8.43 | $13k | 118,231 | Jun 16, 2026 |
| Jun 15, 2026 | IMVT Immunovant, Inc. | SOpen-market sale Common Stock10b5-1 | -1,500 | $34.02 | $51k | 116,731 | Jun 16, 2026 |
| Jun 15, 2026 | IMVT Immunovant, Inc. | MOption exercise Stock Option (right to buy)derivative10b5-1 | -1,500 | $0.00 | $0 | 69,681 | Jun 16, 2026 |
| May 20, 2026 | IMVT Immunovant, Inc. | MOption exercise Common Stock10b5-1 | +6,000 | $8.43 | $51k | 122,731 | May 20, 2026 |
| May 20, 2026 | IMVT Immunovant, Inc. | SOpen-market sale Common Stock10b5-1 | -6,000 | $32.00 | $192k | 116,731 | May 20, 2026 |
| May 20, 2026 | IMVT Immunovant, Inc. | MOption exercise Stock Option (right to buy)derivative10b5-1 | -6,000 | $0.00 | $0 | 270,252 | May 20, 2026 |
| Apr 7, 2026 | IMVT Immunovant, Inc. | AGrant or award Common Stock | +13,880 | $0.00 | $0 | 116,731 | Apr 9, 2026 |
| Apr 7, 2026 | IMVT Immunovant, Inc. | AGrant or award Stock Option (right to buy)derivative | +7,061 | $0.00 | $0 | 7,061 | Apr 9, 2026 |
| Apr 1, 2025 | IMVT Immunovant, Inc. | AGrant or award Common Stock | +16,188 | $0.00 | $0 | 102,851 | Apr 3, 2025 |
| Apr 1, 2025 | IMVT Immunovant, Inc. | AGrant or award Stock Option (right to buy)derivative | +7,600 | $0.00 | $0 | 7,600 | Apr 3, 2025 |
| Dec 2, 2024 | IMVT Immunovant, Inc. | SOpen-market sale Common Stock10b5-1 | -7,750 | $28.54 | $221k | 86,663 | Dec 4, 2024 |
| Dec 1, 2023 | IMVT Immunovant, Inc. | SOpen-market sale Common Stock10b5-1 | -4,129 | $38.80 | $160k | 91,379 | Dec 5, 2023 |
| Dec 1, 2023 | IMVT Immunovant, Inc. | SOpen-market sale Common Stock10b5-1 | -3,374 | $39.82 | $134k | 88,005 | Dec 5, 2023 |
| Dec 1, 2023 | IMVT Immunovant, Inc. | SOpen-market sale Common Stock10b5-1 | -4,847 | $40.46 | $196k | 83,158 | Dec 5, 2023 |
Questions about Atul Pande
Answered from the filings on this page, as of the latest one.
Is Atul Pande buying or selling?
In the last 12 months Atul Pande reported 0 open-market buys worth $0 and 5 open-market sells worth $425k on SEC Form 4; the latest was sold $65k of IMVT on Aug 28, 2026. Grants, option exercises and tax withholding are not counted.
How did Atul Pande's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Atul Pande has 0.
Where does Atul Pande file Form 4?
Atul Pande has filed Form 4 at IMVT (Immunovant, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.